Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

COMPLETED NA

Nicotine Flux, a Potentially Powerful Tool for Regulating Nicotine Delivery From Electronic Cigarettes

NCT05706701 · View on ClinicalTrials.gov ↗

Study Summary

The investigators will examine the relationship between nicotine flux, nicotine form, and the rate and dose of nicotine delivery. Participants will puff on electronic nicotine delivery system (ENDS) devices under conditions that differ by flux and form, while arterial blood is sampled in high time resolution. The outcome will indicate the degree to which nicotine flux and form determine the speed and dose of ENDS nicotine delivery, and thus, abuse liability.

Conditions Studied

Interventions

  • OTHER Nicotine vaping visit 1 (free-base nicotine)
  • OTHER Nicotine vaping visit 1 (protonated nicotine)
  • OTHER Nicotine vaping visit 2 (free-base nicotine)
  • OTHER Nicotine vaping visit 2 (protonated nicotine)

Study Locations (1)

Connecticut

  • Human Research Unit (HRU) — New Haven

Trial Details

FieldValue
Enrollment Target 36 participants
Start Date 2023-02-01
Est. Completion 2024-05-17
Phase NA

Sponsor

Yale University

1,283 total trials

Interested in This Trial?

Always speak with your doctor before enrolling in a clinical trial.

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT05706701

The ClinicalTrials.gov registry entry for NCT05706701 describes a study currently listed as completed. It is categorized as NA, which is the standard way researchers label where a study sits along the investigational pathway from early safety work through later efficacy and post-marketing evaluation. The registered enrollment target is 36 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Yale University, which has 1,283 total studies on file at ClinicalTrials.gov, and sponsors are the parties responsible for study design, oversight, and regulatory filings.

The record links to 1 condition, with Nicotine Vaping appearing as the primary indexed condition, and to 4 interventions — of which Nicotine vaping visit 1 (free-base nicotine) is the first listed. Interventions can include drugs, devices, procedures, behavioral programs, or observational arms, and each is tracked as a separate registry field so that downstream queries can filter accurately. When a trial lists multiple interventions, it usually reflects a multi-arm design or a comparison protocol rather than a single treatment being tested in isolation. The brief summary published in the registry is the clearest source of protocol intent and should be read before drawing conclusions from any sidebar tags.

Geographic footprint matters for practical reasons: NCT05706701 reports 1 study location spanning 1 distinct geographic area — top geographies include Connecticut. A larger site network tends to correlate with broader recruitment capacity, but it does not imply anything about study quality, and site-level enrollment status can diverge from the overall registry status shown above. Every data point on this page comes from the public ClinicalTrials.gov dataset and is reproduced here for reference only; it is not a medical recommendation, an endorsement of the sponsor, or an invitation to enroll. Verify current status, eligibility criteria, and contact details directly at ClinicalTrials.gov, and discuss any participation decision with your own healthcare provider.

Frequently Asked Questions

What is clinical trial NCT05706701 about?

NCT05706701 is a clinical study titled "Nicotine Flux, a Potentially Powerful Tool for Regulating Nicotine Delivery From Electronic Cigarettes". The investigators will examine the relationship between nicotine flux, nicotine form, and the rate and dose of nicotine delivery. Participants will puff on electronic nicotine delivery system (ENDS) devices under conditions that differ by flux and form, while arterial blood is sampled in high time r...

What is the current status of trial NCT05706701?

This trial is currently completed. It is a NA study. The enrollment target is 36 participants. The study started on 2023-02-01. Estimated completion is 2024-05-17.

What conditions does trial NCT05706701 study?

This clinical trial studies the following conditions: Nicotine Vaping. These conditions were identified from the trial registry and reflect the primary focus areas of the research.

What interventions are being tested in trial NCT05706701?

The interventions under investigation include: Nicotine vaping visit 1 (free-base nicotine) (OTHER), Nicotine vaping visit 1 (protonated nicotine) (OTHER), Nicotine vaping visit 2 (free-base nicotine) (OTHER), Nicotine vaping visit 2 (protonated nicotine) (OTHER). Each intervention is being evaluated for safety and efficacy as part of this clinical study.

Who is sponsoring clinical trial NCT05706701?

This trial is sponsored by Yale University, which has 1,283 total clinical trials registered on ClinicalTrials.gov. The sponsor is responsible for the study's design, funding, and regulatory compliance.

Where is trial NCT05706701 being conducted?

This trial has 1 study location across Connecticut. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Related

Data sourced from official U.S. government datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial